MY PICK IS ELN

[billyjoe]

Spike,
Like jiesen it wasn't that ELN was a bad stock, it's just that there's so many others with better prospects. My son is up 92% on EGY in his Roth and that makes me feel very good. Now his MSFT is moving up and I know it may be very conservative but he's got 45 years to wait.
--------billyjoe

[spikefader]

Spike,
Like jiesen it wasn't that ELN was a bad stock, it's just that there's so many others with better prospects. My son is up 92% on EGY in his Roth and that makes me feel very good. Now his MSFT is moving up and I know it may be very conservative but he's got 45 years to wait.
--------billyjoe

Nice. EGY actually just made the cut in a fresh parabolic port this morning too. Aggressive buying up here, but hey, it's parabolic and in an impulse 3 up, and the market is a bull!

[stocks54]

Hello Spike,

My portfolio has 90 % ELAN. I know it's kind of foolish and very risky BUT I think this is the only way to increase capital. If everything works out good than we will see quite a gain in ELAN PSS in next two years.

I have my fingers crossed.

Note: Thanks to kingofthehills for bringing this stock to our attention.

Best Regards,
Stocks54

[New-born baby]

Bodacious

Hello Spike,

My portfolio has 90 % ELAN. I know it's kind of foolish and very risky BUT I think this is the only way to increase capital. If everything works out good than we will see quite a gain in ELAN PSS in next two years.

I have my fingers crossed.

Note: Thanks to kingofthehills for bringing this stock to our attention.

Best Regards,
Stocks54

Stocks,
Crossed fingers generally doesn't make a good indicator of future stock performance. Couldn't you diversify into a few other charts that look explosive for at least a little margin of safety? ELN is a wild stock. Kinda like a bull in a ring. If you can ride it for 8 seconds, you might win the big bucks. On the other hand, it could trample you, too. I like to watch bull riding, but I never sit on a bull because everyone of those guys, sooner or later, get bucked off and stepped on.

I truly hope things work out for you. Best wishes.

[stocks54]

NBB,

Thanks. I am planning to sell some options and hedge my position with some insurance so that if something goes wrong I am covered.

I totally agree that it's very risky play and if (IF) something goes wrong like it did on Black Monday I will be done big time. I think it's my greed to make money more quickly. I am going to slowly start taking out some of it and diversify a bit. I definately think PRX might be a good pick for long term (Reason: Mr. Market's pick at very discounted price).

Best Regards,
Stocks

[jiesen]

ELN's Alzheimer's work is back in the spotlight

http://www.forbes.com/2006/08/25/wyeth-elan-0825markets12.html?partner=yahootix

Alzheimer's Treatments Show Potential: Analyst
Scott Reeves, 08.25.06, 10:28 AM ET

New disease modifying agents for Alzheimer's disease are showing promise, a Cowen and Company analyst believes.
Encouraging results have been seen from MAb therapeutic vaccines from Wyeth (nyse: WYE - news - people ) and Elan (nyse: ELN - news - people ), Neurochem's Alzhemed and Myriad Genetics' Flurizan, according to Cowen analyst Ian Sanderson.
More than 40 compounds are in clinical trials for Alzheimer's disease and about half are disease modifying agents.
"We believe Alzheimer's disease treatments will be an important investment theme for the next several years as successful agents could gain broad combination use and drive a $10 billion to $15 billion market by 2015," Sanderson said.

[kingofthehill]

Just wanted to let you know im alive and well and im buying more Elan .........dont "forget" this stock will have a nice run in 2-4 months time...or sooner...lol

[Websman]

Just wanted to let you know im alive and well and im buying more Elan .........dont "forget" this stock will have a nice run in 2-4 months time...or sooner...lol

It's time for me to take a second look for a possible re-entry. I doubled my money once on ELN. Maybe I can do it again.

[Websman]

I bought ELN back at around $15.23 per share. I may add to my position on a puulback. I believe it's just a matter of time before we see $30.

[Websman]

ELN is looking much better. Watch this doggie run this week...jejeje <TICK>

[stocks54]

It's about time. I have been patiently waiting for it to go to $30. I can’t wait any longer……

[Websman]

It's about time. I have been patiently waiting for it to go to $30. I can’t wait any longer……

It's a long wait, but the ride will be a wild one...

[Websman]

Yet another chance to pick up some cheap shares of ELN. I may buy some more if the price drops some more...

It seems that this analyst is "worried" about Tysabri...LOL What a joke

Analyst Worries About Tysabri
By Althea Chang
TheStreet.com Staff Reporter
9/26/2006 11:40 AM EDT
URL: http://www.thestreet.com/newsanalysis/biotech/10311217.html



Tysabri, the multiple sclerosis treatment from Elan (ELN) and Biogen Idec (BIIB) , appears to be getting hit by the strict safety rules that accompanied the drug's reapproval by regulators, according to one analyst.

Deborah Knobelman of the research firm Piper Jaffray slashed her estimate for worldwide Tysabri sales to $21 million for this year, down from her previous $123 million expectation. According to her feedback from doctors, physicians' adoption rates of the drug were slower than she had anticipated in the U.S. because of safety concerns, reimbursement procedures and patient-monitoring requirements.

Tysabri was recleared by the Food and Drug Administration earlier this year after being taken off the market for fear it could be linked to a potentially fatal brain illness. Before the drug could again go on sale, its makers had to agree to meet a number of criteria dealing with safety monitoring for side effects.

"The current, and in our view, overvalued, [Elan] stock price is not reflective of our new 2006 Tysabri estimates," Knobelman wrote in a research report. "Even if Tysabri revenues reach $1 billion (our peak sales assumption), the stock's current valuation reflects almost double Tysabri's peak potential. We believe [Elan's] Q3 report will reflect our lowered estimates, which might close the stock price's valuation disconnect."

Knobelman maintained an underperform rating on Elan's shares, with a price target of $10. The stock was trading down 14 cents, or 0.9%, at $15.73 Tuesday. Biogen Idec's shares fell 7 cents, or 0.2%, to $44.64.

[jiesen]

Webs, I'm meeting with a friend of mine who's a director of business development at ELN this Friday for dinner. Any particular question(s) you'd like me to bring up?

[Websman]

Webs, I'm meeting with a friend of mine who's a director of business development at ELN this Friday for dinner. Any particular question(s) you'd like me to bring up?

Heck yea Dude! How about getting some good insider info and then PM it to me...jejeje

Seriously though, see what kind of info you can get him to give up. Explain to him that you and a few others hoping to profit from his company.

Maybe King could think of some specific questions. King? Oh King?